Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.31 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431431 | 0.89 | CYP1A2 (0.32) | CYP1A2LMNAKDM4ESMN1; SMN2DUSP3 | |
| SCHEMBL18431433 | 0.89 | CYP1A2 (0.32) | CYP1A2 | |
| SCHEMBL29355928 | 0.87 | LMNA (0.44) | CYP1A2LMNAKDM4ESMN1; SMN2DUSP3 | |
| SCHEMBL2439178 | 0.87 | LMNA (0.44) | CYP1A2LMNAKDM4ESMN1; SMN2DUSP3 | |
| SCHEMBL9656578 | 0.83 | TSHR (0.52) | SMN1; SMN2 | |
| SCHEMBL11660205 | 0.82 | TSHR (0.55) | SMN1; SMN2 | |
| SCHEMBL28922435 | 0.79 | LMNA (0.30) | LMNA | |
| SCHEMBL11588030 | 0.79 | MAPT (0.44) | LMNA | |
| SCHEMBL10716418 | 0.74 | CYP1A2 (0.37) | CYP1A2LMNAKDM4ESMN1; SMN2DUSP3 | |
| SCHEMBL2438756 | 0.74 | LMNA (0.34) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556113-B2 | Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment | THE SOUTH DAKOTA BOARD OF REGENTS (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556113-B2 | Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment | THE SOUTH DAKOTA BOARD OF REGENTS (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556113-B2 | Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment | THE SOUTH DAKOTA BOARD OF REGENTS (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150315131-A1 | COMBINATION USES OF DICHLOROACETATE AND OXAMATE, AND THEIR PRODRUGS, FOR CANCER TREATMENT | SANFORD RESEARCH | 2015-11-05 | — | — | US | disclosed |
| US-20150315131-A1 | COMBINATION USES OF DICHLOROACETATE AND OXAMATE, AND THEIR PRODRUGS, FOR CANCER TREATMENT | SANFORD RESEARCH | 2015-11-05 | — | — | US | disclosed |
| US-20150315131-A1 | COMBINATION USES OF DICHLOROACETATE AND OXAMATE, AND THEIR PRODRUGS, FOR CANCER TREATMENT | SANFORD RESEARCH | 2015-11-05 | — | — | US | disclosed |
| US-20150094331-A1 | QUINOLONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| WO-2011109874-A1 | INHIBITION OF GLUTATHIONE TRANSFERASE ZETA | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094331-A1 | QUINOLONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G12A, PLA2G4A, PLA2G2A | CYP1A2 257/4885LMNA 388/4885KDM4E 3761/4885 |
| US-20150315131-A1 | COMBINATION USES OF DICHLOROACETATE AND OXAMATE, AND THEIR PRODRUGS, FOR CANCER TREATMENT | PDK3, PDK2, PDK4 | CYP1A2 1816/4885LMNA 2839/4885KDM4E 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.